Biocon has reported results for fourth quarter ended March 31, 2012.
On the standalone basis, the company has posted a fall of 29.18% in its net profit at Rs 62.34 crore for the quarter ended March 31, 2012 as compared to Rs 88.03 crore for the same quarter in the previous year. However total income has increased by 14.40% at Rs 432.60 crore for quarter under review as compared to Rs 378.15 crore for the quarter ended March 31, 2011
On the consolidated basis, the company has posted a fall of 2.99% in its net profit at Rs 97.80 crore for the quarter ended March 31, 2012 as compared to Rs 100.81 crore for the same quarter in the previous year. However total income has increased by 29.60% at Rs 610.20 crore for quarter under review as compared to Rs 470.85 crore for the quarter ended March 31, 2011
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.15 |
| Dr. Reddys Labs. | 1350.00 |
| Cipla | 1440.30 |
| Zydus Lifesciences | 1101.50 |
| Lupin | 2342.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: